Kenneth J. Mandell, M.D., Ph.D. President and CEO at LayerBio, Inc., Presentation
Jacqueline Thong is the co-founder and CEO at Klio Healthan. Presentation
Dr. Chaturvedi is the Founder and Chairman of Boston-based IndUS Pharmaceuticals. Presentation
Jim Jenson, PhD is a life-science entrepreneur. Presentation
The term 'Lean Start-Up' may mean different things to people involved in different business sectors, but the bottom line for everybody is the same. Lean startups focus on getting to marketed products or to significant product development value inflections with minimum expenditures of capital and time. It’s a good thing! Join us for an interactive discussion with a panel of entrepreneurs with very different lean startups.
Kenneth J. Mandell
, M.D., Ph.D. President and CEO at LayerBio, Inc., http://www.layerbio.com
Dr. Mandell is an innovative entrepreneur. In his current role as President and CEO of LayerBio, he is leading the development of a new biotechnology company with a focus on drug delivery. An ophthalmologist-by-training with extensive drug development expertise, Dr. Mandell has developed novel drugs and drug delivery approaches for various topical and injectable applications. He previously served as VP of Early Development at Liquidia, President & COO at Xcovery Vision and Scientific Director at ORA. He is an MIT Affiliate and co-inventor of LayerForm™ technology. In addition to experience overseeing R&D and operations in multiple start-up companies, he has consulted for a number of biotech companies providing due diligence, technology assessment, portfolio prioritization and other services.
is the co-founder and CEO at Klio Healthan. She is an experienced entrepreneur, who has over 15 years of experience in software and health IT, in roles ranging from sales and marketing to system design and project management. Prior to founding Klio Health, Jacqueline was an early member of CRF Health, one of the leading providers of electronic patient diary systems for the clinical trials industry. In her career at CRF Health, she managed the implementation of patient data capture systems in over 50 Phase II and III clinical trials for global pharmaceutical companies across a variety of therapeutic areas. She was also previously on the management team of a venture-backed software startup in Helsinki, Finland. Jacqueline completed her undergraduate degree in Marketing and Information Systems at the University of British Columbia in Vancouver, BC, and she holds an MBA from INSEAD.
is the Founder and Chairman of Boston-based IndUS Pharmaceuticals and a co-founder of Florida-based Oceanyx Pharmaceuticals and also serves as the Chief Executive Officer of both these organizations. He also serves as the Chief Scientific Officer of San Francisco-based Napo Pharmaceuticals. Previously he has served as the President and Chief Executive Officer of Boston-based Scion Pharmaceuticals. Dr. Chaturvedi serves on the boards of IndUS, Oceanyx, FuelEd Schools, Cellanyx, PRADAN USA and Sindu Research Laboratories. He has previously served on the Boards of Scion Pharmaceuticals and TiE Boston. He also serves as an advisory board member to TFC Biosciences and Springboard Enterprises and is the Chair of the Research Advisory Council for the Health Sciences Center of West Virginia University. He is an adjunct faculty member at Georgetown Medical School.
Over his 25+ year career, Dr. Chaturvedi has participated or led the discovery and/or development activities for several new chemical entities (NCEs), culminating in the successful development and commercialization of seven new drugs that are currently marketed by various companies. Prior to his roles at Napo, IndUS, Oceanyx and Scion Pharmaceuticals, Dr. Chaturvedi, spent several years at Vertex Pharmaceuticals as the Head of Lead Evaluation. Prior to Vertex, he was in the preclinical group at Alkermes and he started his R&D career in the Product Development group at Parke-Davis/Warner- Lambert Company (now Pfizer). Dr. Chaturvedi holds a Ph.D. in Pharmaceutical Sciences from West Virginia University and a Bachelor’s in Pharmacy from the University of Bombay.
, PhD is a life-science entrepreneur and executive with 30 years experience in the pharmaceutical and biotechnology industries. He is currently CEO and Co-Founder of Sabik Medical Inc., based in Boston. Sabik is a biotech company developing a new radiopharmaceutical technology for the imaging and treatment of cancer, with an initial focus on prostate cancer. Previously, he was CEO and co-Founder with Doug Fambrough of Dicerna Pharmaceuticals, Inc. located in Watertown, Massachusetts. Dicerna is a public company developing novel therapeutics for multiple indications based on ‘Dicer Substrate’ technology, which makes use of the RNA interference mechanism (RNAi). Dicerna completed an upsized IPO in January 2014. Prior to Dicerna, Jim was CEO and co-Founder of Zapaq Inc., which later merged with another company to form CoMentis. The Company’s orally bioavailable, brain accessible beta-secretase enzyme inhibitor was licensed to Astellas, and was the first for this target to enter clinical trials for Alzheimer’s Disease. Prior to Zapaq, Jim served in a variety of roles at Procept; Triton/Berlex/Schering A.G.; and Hoffmann-LaRoche. Jim holds a PhD in Biology and Biochemistry from Cornell University and a BA in Biology from Macalester College.
Dr. Roger Frechette
is the Co-Founder and Principal of New England PharmAssociates, a consultancy offering on-demand executive and business advisory services to life sciences enterprises. He is also the US East Coast Ambassador for Medicon Valley Alliance, a life sciences cluster organization based in Copenhagen. Previously, he was a Co-Founder of Frontiera Therapeutics, a startup developing therapeutics for vascular leaks. He is a volunteer adviser and mentor with several Boston area biotech incubators and startup mentoring programs. Previously, Dr. Frechette was Co-Founder of MaxThera, an antibacterial drug discovery company. MaxThera was sold in 2010 to Biota Holdings Limited, a Melbourne Australia anti-infectives company. Prior to starting MaxThera, Dr. Frechette was a drug discovery and life-sciences consultant following his role as Project Director at Paratek Pharmaceuticals (Boston). At Paratek he led the team that discovered PTK0796 (currently in Phase III clinical trials) with strategic partner Glaxo-Wellcome, and the pre-clinical development program that was carried out with a multinational team of consultants and contractors. Previously, he was Associate Director of Chemistry at RiboGene (Hayward, CA), where he built the chemistry department and managed two drug discovery programs in collaboration with strategic partner Dainippon Pharmaceuticals. He began his career as a medicinal chemist at the R.W. Johnson Pharmaceutical Research Institute (J&J, Raritan, NJ). Dr. Frechette was a Post-Doctoral Fellow at Yale University, earned his PhD in Organic Chemistry from Wesleyan University and his BA in Chemistry from College of the Holy Cross.